ABCB1 in children's brain tumours

Biochemical Society Transactions

Volumn 43, Issue , 2015, Pages 1018-1022

  Coyle, Beth ^a   Kessler, Maya ^a   Sabnis, Durgagauri H ^a   Kerr, Ian D ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ABCB1; Cancer stem cells; Drug resistance; Ependymoma; Medulloblastoma

Indexed keywords

ABC TRANSPORTER; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; ABCB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); EPENDYMOMA; HUMAN; MEDULLOBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; DRUG RESISTANCE; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BRAIN NEOPLASMS; CEREBELLAR NEOPLASMS; CHILD; DRUG RESISTANCE, NEOPLASM; EPENDYMOMA; HUMANS; MEDULLOBLASTOMA; P-GLYCOPROTEINS;

EID: 84947207360     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150137     Document Type: Article

References (30)

1. Grundy, R.G., Wilne, S.A., Weston, C.L., Robinson, K., Lashford, L.S., Ironside, J., Cox, T., Chong, W.K., Campbell, R.H., Bailey, C.C. et al. (2007) Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8, 696-705 CrossRef PubMed
2. Ellison, D.W., Kocak, M., Figarella-Branger, D., Felice, G., Catherine, G., Pietsch, T., Frappaz, D., Massimino, M., Grill, J., Boyett, J.M. et al. (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J. Negat. Results Biomed. 10, 7 CrossRef PubMed
3. Merchant, T.E., Li, C., Xiong, X., Kun, L.E., Boop, F.A. and Sanford, R.A. (2009) Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol 10, 258-266 CrossRef PubMed
4. Zacharoulis, S., Levy, A., Chi, S.N., Gardner, S., Rosenblum, M., Miller, D.C., Dunkel, I., Diez, B., Sposto, R., Ji, L. et al. (2007) Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr. Blood Cancer 49, 34-40 CrossRef PubMed
5. Grill, J., Le Deley, M.C., Gambarelli, D., Raquin, M.A., Couanet, D., Pierre-Kahn, A., Habrand, J.L., Doz, F., Frappaz, D. and Gentet, J.C. (2001) Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J. Clin. Oncol. 19, 1288-1296 PubMed
6. Massimino, M., Gandola, L., Barra, S., Giangaspero, F., Casali, C., Potepan, P., Di Rocco, C., Nozza, P., Collini, P., Viscardi, E. et al. (2011) Infant ependymoma in a 10-year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 80, 807-814 CrossRef PubMed
7. Bouffet, E. and Foreman, N. (1999) Chemotherapy for intracranial ependymomas. Childs Nerv. Syst. 15, 563-570 CrossRef PubMed
8. Atkinson, J.M., Shelat, A.A., Carcaboso, A.M., Kranenburg, T.A., Arnold, L.A., Boulos, N., Wright, K., Johnson, R.A., Poppleton, H., Mohankumar, K.M. et al. (2011) An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell 20, 384-399 CrossRef PubMed
9. Taylor, M.D., Northcott, P.A., Korshunov, A., Remke, M., Cho, Y.J., Clifford, S.C., Eberhart, C.G., Parsons, D.W., Rutkowski, S., Gajjar, A. et al. (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123, 465-472 CrossRef PubMed
10. Northcott, P.A., Jones, D.T., Kool, M., Robinson, G.W., Gilbertson, R.J., Cho, Y.J., Pomeroy, S.L., Korshunov, A., Lichter, P., Taylor, M.D. et al. (2012) Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12, 818-834 CrossRef PubMed
11. Pizer, B.L. and Clifford, S.C. (2009) The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. Br. J. Neurosurg. 23, 364-375 CrossRef PubMed
12. Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M., Cusimano, M.D. and Dirks, P.B. (2004) Identification of human brain tumour initiating cells. Nature 432, 396-401 CrossRef PubMed
13. Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D. and Rich, J.N. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 7120, 756-760 CrossRef PubMed
14. Szakács, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C. and Gottesman, M.M. (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219-234 CrossRef PubMed
15. Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P. et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77, 491-502 CrossRef PubMed
16. Zeppernick, F., Ahmadi, R., Campos, B., Dictus, C., Helmke, B.M., Becker, N., Lichter, P., Unterberg, A., Radlwimmer, B. and Herold-Mende, C.C. (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14, 123-129 CrossRef PubMed
17. Cheng, J.X., Liu, B.L. and Zhang, X. (2009) How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat. Rev. 35, 403-408 CrossRef PubMed
18. Hirschmann-Jax, C., Foster, A.E., Wulf, G.G., Nuchtern, J.G., Jax, T.W., Gobel, U., Goodell, M.A. and Brenner, M.K. (2004) A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 101, 14228-14233 CrossRef PubMed
19. Hussein, D., Punjaruk, W., Storer, L.C., Shaw, L., Othman, R., Peet, A., Miller, S., Bandopadhyay, G., Heath, R., Kumari, R., Bowman, K.J. et al. (2011) Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusion. Neuro. Oncol. 13, 70-83 CrossRef PubMed
20. Othman, R.T., Kimishi, I., Bradshaw, T.D., Storer, L.C., Korshunov, A., Pfister, S.M., Grundy, R.G., Kerr, I.D. and Coyle, B. (2014) Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathol. Commun. 2, 57 CrossRef PubMed
21. Weinstein, R.S., Jakate, S.M., Dominguez, J.M., Lebovitz, M.D., Koukoulis, G.K., Kuszak, J.R., Klusens, L.F., Grogan, T.M., Saclarides, T.J., Roninson, I.B. et al. (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51, 2720-2726 PubMed
22. Randolph, G.J., Beaulieu, S., Pope, M., Sugawara, I., Hoffman, L., Steinman, R.M. and Muller, W.A. (1998) A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. Proc. Natl. Acad. Sci. U.S.A. 95, 6924-6929 CrossRef PubMed
23. Miletti-Gonzalez, K.E., Chen, S., Muthukumaran, N., Saglimbeni, G.N., Wu, X., Yang, J., Apolito, K., Shih, W.J., Hait, W.N. and Rodriguez-Rodriguez, L. (2005) The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65, 6660-6667 CrossRef PubMed
24. Colone, M., Calcabrini, A., Toccacieli, L., Bozzuto, G., Stringaro, A., Gentile, M., Cianfriglia, M., Ciervo, A., Caraglia, M., Budillon, A. et al. (2008) The multidrug transporter P-glycoprotein: a mediator of melanoma invasion? J. Invest. Dermatol. 128, 957-971 CrossRef PubMed
25. Aversa, A., Pili, M., Francomano, D., Bruzziches, R., Spera, E., La Pera, G. and Spera, G. (2009) Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation. Int. J. Impot. Res. 21, 221-227 CrossRef PubMed
26. Wardle, A.J. and Tulloh, R.M. (2013) Paediatric pulmonary hypertension and sildenafil: current practice and controversies. Arch. Dis. Child. Educ. Pract. Ed. 98, 141-147 CrossRef PubMed
27. Bischoff, E. (2004) Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int. J. Impot. Res. 16 Suppl 1, S34-S37 CrossRef PubMed
28. Ding, P.R., Tiwari, A.K., Ohnuma, S., Lee, J.W.K.K., An, X., Dai, C.L., Lu, Q.S., Singh, S., Yang, D.H. and Talele, T.T. (2011) The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One 6, e19329 CrossRef PubMed
29. Black, K.L., Yin, D., Ong, J.M., Hu, J., Konda, B.M., Wang, X., Ko, M.K., Bayan, J.A., Sacapano, M.R., Espinoza, A. et al. (2008) PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res. 290-302
30. Hu, J., Ljubimova, J.Y., Inoue, S., Konda, B., Patil, R., Ding, H., Espinoza, A., Wawrowsky, K.A., Patil, C. and Ljubimov, A.V. (2010) Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One 5, e10108 CrossRef PubMed